IDEXX Laboratories, Inc.
Profit after direct costs
Core business profitability
Bottom line profitability
Top line growth rate
Flow of revenue through cost categories to net income
| Item | Trend | 2021 | 2022 | 2023 | 2024 | 2025 | YoY Change |
|---|---|---|---|---|---|---|---|
Total Revenue | 3.22B | 3.37B | 3.66B | 3.90B | 4.30B | 10.4% | |
| Cost of Revenue | (1.33B) | (1.36B) | (1.47B) | (1.52B) | (1.64B) | 8.3% | |
Gross Profit | 1.89B | 2.00B | 2.19B | 2.38B | 2.66B | 11.8% | |
| Operating Expenses | |||||||
| Research & Development | (161.01M) | (254.82M) | (190.95M) | (219.79M) | (251.21M) | 14.3% | |
| Selling, General & Administrative | (796.39M) | (850.75M) | (901.89M) | (1.03B) | (1.05B) | 1.7% | |
| General & Administrative | (309.66M) | (326.25M) | (335.82M) | (442.29M) | (404.79M) | -8.5% | |
| Selling & Marketing | (486.74M) | (524.50M) | (566.07M) | (588.51M) | (643.55M) | 9.4% | |
| Depreciation & Amortization | (104.60M) | (111.90M) | (114.91M) | (129.94M) | (106.46M) | -18.1% | |
Operating Income (EBIT) | 932.03M | 898.76M | 1.10B | 1.13B | 1.36B | 20.5% | |
| Non-Operating Items | |||||||
| Interest Income | 434.00K | 1.06M | 5.63M | 12.70M | 2.42M | -80.9% | |
| Interest Expense | (29.81M) | (39.86M) | (41.58M) | (31.20M) | (38.27M) | 22.6% | |
| Other Income/Expenses (Net) | -29.37M | -38.79M | -35.95M | -18.51M | -35.84M | 93.7% | |
Income Before Tax | 902.65M | 859.97M | 1.06B | 1.11B | 1.32B | 19.3% | |
| Income Tax Expense | (157.81M) | (180.88M) | (216.13M) | (221.96M) | (264.73M) | 19.3% | |
Net Income | 744.85M | 679.09M | 845.04M | 887.87M | 1.06B | 19.3% | |
| Per Share Metrics | |||||||
| Earnings Per Share (Basic) | $9 | $8 | $10 | $11 | $13 | 22.3% | |
| Weighted Avg Shares Outstanding | 85.20M | 83.62M | 83.07M | 82.47M | 80.10M | -2.9% | |
| Weighted Avg Shares Outstanding (Diluted) | 86.57M | 84.60M | 83.98M | 83.25M | 80.67M | -3.1% | |
EBITDA | 1.04B | 1.01B | 1.22B | 1.28B | 1.47B | 15.1% |
Explore IDXX
IDXX in the Healthcare
Large Cap